[Corticosteroid therapy of multiple sclerosis with attention to biorhythms].
The corticosteroid therapy of multiple sclerosis was modified in relation to the biorhythms of the hypothalamic-pituitary-adrenal axis (HPAA). Prednisolone was prescribed per os in a dose of 1.5 mg/kg bw daily to be taken only in the morning once every three days for 30-45 days. In the control group, prednisolone was administered daily in a dose of 30-60 mg. In the test group, remissions were attained even in hormone-resistant forms of the disease and HPAA function was not seriously affected. Unlike control patients, no severe and persistent complications were observed in that group. The authors believe that the emergence of such complications following the corticosteroid treatment is partially related to the iatrogenic desynchronism of the regulatory biorhythmical processes in the HPAA with the suppression and perversion of adrenal function of steroidogenesis.
D000303:Adrenal Cortex Diseases / Q000139:chemically induced; D000305:Adrenal Cortex Hormones / Q000032:analysis*; D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010507:Periodicity; D010900:Pituitary Diseases / Q000139:chemically induced; D010913:Pituitary-Adrenal System / Q000502:physiology*; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D011239:Prednisolone
Kortikosteroidnaia terapiia rasseiannogo skleroza s uchetom bioritmov.